In two pilot clinical trials, buprenorphine helped participants reduce their illicit opioid use and injection drug use while awaiting admission to a methadone or buprenorphine treatment program. Researchers minimized the risks for improper use or diversion of the study medication by giving it to trial participants in a computerized, tamper-proof device that dispenses one dose each day.
New studies show that two novel compounds powerfully suppressed animals’ pain responses, while producing little or none of the respiratory depression and liability for misuse and abuse associated with morphine and other typical opioids.
The Strengthening Families Program for Youth 10-14 (SFP10-14), an evidence-based intervention that reduces teen substance use, also reduced participants’ friends’ substance use. Two factors that accounted for the nonparticipants’ reductions were less time spent by nonparticipants with their participating friends without adult supervision and improvements in nonparticipants’ attitudes toward substance use. The findings suggest that researchers should consider the potential for diffusion of benefits in designing and implementing prevention programs.
Women face unique challenges on the road to recovery. Often, coed treatment programs can’t or don’t address them all. Fortunately, addiction treatment dedicated to women is an option. Explore the… Read more »
Throughout time, young people have been curious about the world. Experimentation and exploration are normal for teenagers. However, teen drug abuse is not something that can be overlooked or ignored…. Read more »
There is a common misconception that drug addiction is specific to certain demographics or certain areas. The truth is that drug addiction can develop anywhere. In the United States, certain… Read more »
Recovering from alcoholism is virtually synonymous with AA. Although many people are familiar with the idea of Alcoholics Anonymous, fewer people know what goes on behind closed doors. Getting familiar… Read more »